DR. ALAN H CHENG, D.C.
Chiropractic at Lombard St, San Francisco, CA

2011025, Oct 13, 2011

Mar 14, 2011

13/047734

Yuan CHENG - Newbury Park CA, US
Ryan White - Somerville MA, US
Albert Amegadzie - Moorpark CA, US
James Brown - Moorpark CA, US
Alan C. Cheng - San Francisco CA, US
Erin F. Dimauro - Cambridge MA, US
Thomas Dineen - Somerville MA, US
Oleg Epstein - Belmont MA, US
Vijay Keshav Gore - Thousand Oaks CA, US
Jason Brooks Human - Boston MA, US
Ted Judd - Simi Valley CA, US
Charles Kreiman - Watertown MA, US
Qingyian Liu - Camarillo CA, US
Patricia Lopez - West Hills CA, US
Vu Van Ma - Simi Valley CA, US
Isaac Marx - Somerville MA, US
Ana Minatti - Woodland Hills CA, US
Hanh Nho Nguyen - Arlington MA, US
Nick A. Paras - Glendale CA, US
Vinod F. Patel - Acton MA, US
Wenyuan Qian - Camarillo CA, US
Matthew Weiss - Boston MA, US
Qiufen Xue - Newbury Park CA, US
Xiao Mei Zheng - Natick MA, US
Wenge Zhong - Thousand Oaks CA, US

Amgen Inc. - Thousand Oaks CA

A61K 31/538, A61K 31/436, C07D 413/14, C07D 417/14, A61K 31/444, A61P 25/00, C07D 513/10, A61K 31/4545, C07D 498/10, A61K 31/497, A61P 25/28, A61P 25/16, C07D 513/20, A61K 31/506

5142305, 546 18, 514278, 544105, 546256, 514333, 544333, 514256, 546194, 514318, 544405, 51425505

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and other related conditions. In one embodiment, the compounds have a general Formula Iwherein A, A, A, A, A, A, R, R, X and Y of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

2013021, Aug 22, 2013

Jul 28, 2011

13/813813

Christiane M. Boezio - Somerville MA, US
Alan C. Cheng - San Francisco CA, US
Deborah Choquette - Medford MA, US
Richard T. Lewis - Framingham MA, US
Michele H. Potashman - Cambridge MA, US
Karina Romero - Arlington MA, US
John C. Stellwagen - Beverly MA, US
Douglas A. Whittington - Waltham MA, US

AMGEN INC. - Thousand Oaks CA

C07D 471/04, C07D 401/10, C07D 413/14, C07D 401/14, C07D 417/14, C07D 403/08, C07D 235/30, C07D 413/10

51421018, 546118, 5483074, 546199, 544139, 544364, 544127, 5483061, 544 582, 514303, 514388, 514322, 5142345, 51425309, 5142342, 51425304

Compounds of Formula (I) are useful inhibitors of anaplastic lymphoma kinase. Compounds of Formula (I) have the following structure: where the definitions of the variables are provided herein.

2012019, Jul 26, 2012

May 12, 2010

13/319683

Christiane Bode - Somerville MA, US
Alessandro Boezio - Somerville MA, US
Alan C. Cheng - San Francisco CA, US
Deborah Choquette - Medford MA, US
James Robert Coats - Oak Harbor WA, US
Katrina Woodin Copeland - Sudbury MA, US
Hongbing Huang - Lexington MA, US
Daniel La - Brookline MA, US
Richard Thomas Lewis - Framingham MA, US
Hongyu Liao - Thousand Oaks CA, US
Michele Potashman - Cambridge MA, US
John Stellwagen - Beverly MA, US
Shuyan Yi - Cambridge MA, US
Mark H. Norman - Thousand Oaks CA, US
Markian M. Stec - Moorpark CA, US
Emily Anne Peterson - Cambridge MA, US
Russell Graceffa - Hampton NH, US

Amgen Inc. - Thousand Oaks CA

A61K 31/52, C07D 401/14, A61K 31/506, A61P 35/02, A61K 31/53, C07D 487/04, A61K 31/5377, A61P 35/00, C07D 473/40, C07D 471/04

51421021, 544264, 51426323, 544328, 514256, 544212, 514245, 544236, 514248, 544296, 544117, 5142332

The present invention provides compounds that are PIKK inhibitors, more specifically, mTOR and/or PI3Kα kinase inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of kinases, specifically PI3 kinases, more specifically, mTOR and/or PI3Kα, such as cancer. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

2012016, Jun 28, 2012

Feb 10, 2010

13/260715

Alessandro Boezio - Somerville MA, US
Alan C. Cheng - San Francisco CA, US
James Robert Coats - Oak Harbor WA, US
Katrina Woodin Copeland - Sudbury MA, US
Russell Graceffa - Hampton NH, US
Hongbing Huang - Lexington MA, US
Daniel La - Brookline MA, US
Philip R. Olivieri - Charleston MA, US
Emily Anne Peterson - Garobridge MA, US
Laurie Schenkel - Boston MA, US

AMGEN INC. - Thousand Oaks CA

A61K 31/53, A61P 35/00, C07D 403/04, A61K 31/506, C07D 401/14, C07D 403/14

514245, 544209, 544328, 514256, 544324, 514275

The present invention provides compounds that are kinase inhibitors, specifically PIK kinase inhibitors, more specifically, mTOR inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of kinases, specifically PIK kinase inhibitors, more specifically, mTOR such as cancer. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.